GlobeNewswire Medical EquipmentQwen · 实盘不做把握 1/10不做原因:不是事件
北京时间·🕒 发布 19:30:00·⟳ 抓取 19:31:56·⚡ 决策 09-01 19:33:53 +1m57s·56.3 天前
FocalTherics宣布CEO将于9月15日在H.C. Wainwright第28届全球投资会议上做演讲
这是一条标准的投资会议演讲预告公告，仅宣布CEO将在两周后的会议上发言并举行1对1投资者会议。没有任何新增事实（无临床数据、无监管进展、无财务指引、无订单、无合作），不构成任何方向性催化。即使会议当天有实质内容发布，那也是9月15日的事件，不是今天的公告。
📄 原文GlobeNewswire Medical Equipment↗ 原文
FocalTherics™ to Present at the H.C. Wainwright 28th Annual Global Investment Conference
FocalTherics ™ to Present at the H.C. Wain w right 28 th Annual Global Investment Conference Company to Present and Hos…
不做 FocalTherics（FOCL.US）
例行投资会议演讲预告，不携带任何新增基本面信息（无临床数据、无监管进展、无财务指引、无订单、无合作），不构成交易催化。会议在两周后举行，届时若有实质内容才值得重新评估。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
FocalTherics于2026年9月1日发布GlobeNewswire通稿，宣布CEO将于9月15日在H.C. Wainwright第28届全球投资会议上做演讲。这是上市公司最常见的例行公告之一，不携带任何新增基本面信息。会议本身在两周后举行，届时若有实质内容（如临床数据、商业化进展）才可能构成催化，但今天的预告公告本身无任何交易价值。结论：无事件、无增量事实，不做。
🔎 新鲜度:最早出现 2026-09-01 · 扩散 low · price-in 风险 low ↗
先例如何影响了这次决策
对本次决策的影响:无先例需求，事件本身不构成催化
方向:不适用——会议演讲预告类事件在学术和实务中均被认定为无催化事件，无需先例统计
涨幅量级:不适用
形态:不适用
原文全文
展开原文 · 1,583 字
FocalTherics
™
to Present at
the
H.C. Wain
w
right
28
th
Annual Global Investment Conference
Company to Present and Host 1x1 Investor Meetings on
T
uesday
and Wednesday, September 15
th
-16
th
, 2026
AUSTIN, Texas, Sept. 01, 2026 (GLOBE NEWSWIRE) -- FocalTherics™ (Nasdaq: FOCL) (the “Company”), a global leader in robotic focal therapy, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to present at the upcoming H.C. Wainwright 28th Annual Global Investment Conference being held September 14-16, 2026 in New York, New York. Rhodes, together with Ken Mobeck, Chief Financial Officer, will also host 1x1 investor meetings at the conference on Tuesday and Wednesday, September 15-16, 2026.
Date
: Tuesday, September 15, 2026
Time
: 10:30-11:00 AM ET
Format
: Presentation
Webcast
:
https://journey.ct.events/view/678a5096-f9a4-4a67-b503-ad650aca3c59
The live and archived webcast of the presentation can be accessed in the Investors section of the Company’s website
here
.
About
FocalTherics
A recognized global leader in robotic focal therapy, FocalTherics develops, manufactures, and markets minimally invasive medical devices worldwide to treat various conditions using proprietary focused ultrasound technology. The Company’s flagship platform, Focal One® Robotic HIFU, combines advanced imaging, real-time treatment planning, robotic precision, and HIFU technology to deliver personalized focal therapy designed to optimize clinical outcomes while preserving quality of life.
Investor Contact
Louisa Smith
Gilmartin Group
Investor.relations@focalone.com
™
to Present at
the
H.C. Wain
w
right
28
th
Annual Global Investment Conference
Company to Present and Host 1x1 Investor Meetings on
T
uesday
and Wednesday, September 15
th
-16
th
, 2026
AUSTIN, Texas, Sept. 01, 2026 (GLOBE NEWSWIRE) -- FocalTherics™ (Nasdaq: FOCL) (the “Company”), a global leader in robotic focal therapy, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to present at the upcoming H.C. Wainwright 28th Annual Global Investment Conference being held September 14-16, 2026 in New York, New York. Rhodes, together with Ken Mobeck, Chief Financial Officer, will also host 1x1 investor meetings at the conference on Tuesday and Wednesday, September 15-16, 2026.
Date
: Tuesday, September 15, 2026
Time
: 10:30-11:00 AM ET
Format
: Presentation
Webcast
:
https://journey.ct.events/view/678a5096-f9a4-4a67-b503-ad650aca3c59
The live and archived webcast of the presentation can be accessed in the Investors section of the Company’s website
here
.
About
FocalTherics
A recognized global leader in robotic focal therapy, FocalTherics develops, manufactures, and markets minimally invasive medical devices worldwide to treat various conditions using proprietary focused ultrasound technology. The Company’s flagship platform, Focal One® Robotic HIFU, combines advanced imaging, real-time treatment planning, robotic precision, and HIFU technology to deliver personalized focal therapy designed to optimize clinical outcomes while preserving quality of life.
Investor Contact
Louisa Smith
Gilmartin Group
Investor.relations@focalone.com
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。